February 3, 2010 (FinancialWire) — Tongjitang Chinese Medicines Co. (NYSE: TCM), a specialty pharmaceutical company, said that it has set up a joint venture with a third party to acquire 100% of state-owned Guiyang Liquor Factory for RMB120.6 million in cash.

Tongjitang owns 95% of the joint venture and said it will pay its share of the consideration in full by February 2010. This acquisition is scheduled to be completed in the first quarter of 2010.

Guiyang Liquor manufactures and sells three brands of Chinese liquors: “Guiyang Da Qu,” “Qian Chun Liquor” and “Gui Liquor.” Tongjitang said that, according to its audited financial statements, Guiyang Liquor was profitable and achieved revenues of RMB18.9 million in 2008. Guiyang Liquor was founded in 1958 and is located in Guiyang City, Guizhou Province, China.

China-based Tongjitang Chinese Medicines, through its operating subsidiaries, is a vertically integrated specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.